Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.21 USD
Change Today -0.01 / -4.55%
Volume 417.0
CAPS On Other Exchanges
Symbol
Exchange
OTC US
As of 5:20 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

capstone therapeutics corp (CAPS) Key Developments

Capstone Therapeutics Corp. and LipimetiX Development, Inc. Announce Patent Application for Novel, More Potent Chimeric Apo E Mimetic Peptides

Capstone Therapeutics Corp. and its joint venture affiliate, LipimetiX Development, Inc. ("JV"), announced the conversion of a provisional U.S. Patent application claiming novel, more potent analogs of its lead peptide, AEM-28. The JV has supported research by Dr. G.M. Anantharamaiah at the University of Alabama, Birmingham to identify novel analogs of AEM-28 that demonstrate greater efficacy than the parent peptide and provide new composition of matter patent protection. One of the new, chimeric Apo E mimetic peptides (AEM-28-14), tested in multiple, validated animal models, demonstrates up to 400% greater cholesterol lowering efficacy and a several fold increase in the NOAEL (No Observed Adverse Effect Level) dose, a primary indicator of drug tolerability. The combination of enhanced efficacy and toleration potentially increases the therapeutic window (the range for delivering a safe and efficacious dose) significantly over previous analogs of AEM-28.

Capstone Therapeutics Corp., Q1 2015 Earnings Call, May 28, 2015

Capstone Therapeutics Corp., Q1 2015 Earnings Call, May 28, 2015

Capstone Therapeutics Corp. Proposes to Amend Certificate of Incorporation

Capstone Therapeutics Corp. proposed to amend the company's amended and restated certificate of incorporation to increase the number of authorized shares of common stock from 100,000,000 to 150,000,000, at the AGM to be held on June 19, 2015.

Capstone Therapeutics Corp., Annual General Meeting, Jun 19, 2015

Capstone Therapeutics Corp., Annual General Meeting, Jun 19, 2015., at 13:00 US Mountain Standard Time. Location: 1275 West Washington Street. Agenda: To elect one director as a class III director to serve until the annual meeting of stockholders to be held in the year 2018, or until a successor is elected and qualified; to consider and act upon a proposal to ratify and approve the company's 2015 equity incentive plan; to consider and act upon a proposal to amend the company's amended and restated certificate of incorporation to increase the number of authorized shares of common stock from 100,000,000 to 150,000,000; to ratify the appointment of Moss Adams LLP, as the company's independent registered public accounting firm for the fiscal year ending December 31, 2015; and to transact such other business as may properly come before the annual meeting or any adjournment thereof.

Capstone Therapeutics Corp. - Shareholder/Analyst Call

Capstone Therapeutics Corp. - Shareholder/Analyst Call

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CAPS:US $0.21 USD -0.01

CAPS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CAPS.
View Industry Companies
 

Industry Analysis

CAPS

Industry Average

Valuation CAPS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CAPSTONE THERAPEUTICS CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.